Patients taking oral doses of perhexiline maleate have been examined. Measurement of serum perhexiline concentrations established that different dose requirements between patients were necessary due to the different doses at which drug saturation was achieved. Measurement of serum perhexiline concentrations are essential if side-effects from the drug are to be avoided.
Although perhexiline maleate (Px), 2-(2,2dicyclohexylethyl)-piperidine, is known to be effective as an anti-anginal agent, I, 2 it can produce severe side-effects (hepatoxicity' and neuropathy."
The development of these side-effects are reported to correlate with high concentrations of Px in blood.i' due to the varying ability of patients to metabolise the drug to the monohydroxylate metabolite. Attempts by Shah et al. 6 to phenotype the slow and fast metabolisers of the drug using a single debrisoquine loading test proved inconclusive. Following the development of a gas chromatographic procedure for the rapid estimation of serum Px, 7 Pilcher et al. 8 have shown that high concentrations of Px in patients can be avoided provided that serum Px concentrations are carefully monitored and that there is a relationship between therapeutic response and serum Px concentrations. This paper reports on the observed differences of Px doses and the corresponding serum Px concentrations obtained between patients, and underlines the importance of monitoring the serum concentration of this drug when used therapeutically.
Methods

PATIENTS
Nineteen males, who had not before received
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Px therapy, were used in this investigation. These patients were chosen because their angina did not respond to other treatment. All previous therapies were continued. On each visit to the cardiology clinic patients were examined, weighed and blood taken for routine laboratory tests and Px measurements. Blood samples were taken as far as possible at the same time of the day on each occasion and at a similar interval after the last dose of Px. Drug concentrations vary very little, however, throughout the day in patients who have achieved steady state.
DOSE CHANGES
All patients were started on 100 mg Pxdaily. This dose was increased to 200 mg daily after 2 weeks unless good clinical response had been achieved or subjective side-effects (eg, dizziness, blurred vision) or raised serum liver enzymes had occurred. Patients were seen 2-8 weeks later and the dose increased to 300 mg daily if no clinical response and no side-effects had occurred. Thereafter, they were seen every 3 months or more frequently. Results of the serum Px concentration were not made available to clinicians until the end of the study unless concentrations exceeded 2·0 mg/L and dose reductions were immediately required. During the study reductions of the daily Px dose were made by the clinician on the basis of any side-effects. Increased dosage above 300 mg per day was rare, but occurred when anginal response was poor. One patient required a 600 mg daily dose to obtain sufficient therapeutic response. SERUM Px MEASUREMENTS Serum Px was estimated using the procedure described by Cooper and Turnell." The technique used a single ether extraction of the drug from serum and was shown to be free from interference by other cardiogenic drugs like beta blockers. Between-batch precision was found to be 13·1% and 5·2% for serum Px concentrations of 0·5 and 3·0 mgfL, respectively. The limit of detection by the procedure used was 0·04 mg/L.
Results and discussion
Therapeutic management of many drugs is difficult, especially where the human pharmokinetics of such compounds is poorly understood. For the management of Px, clinicians usually rely on the integrity of the patient, information from the manufacturer, clinical response and observations on the subjective and objective side-effects.
Px is a drug where clinical management alone is insufficient if side-effects are to be avoided; in a previous article it has been shown that measurement of serum Px concentrations can help to eliminate toxic side-effects." A further reason to support this argument can be seen in the results of this study. Figure 1 shows every serum Px concentration obtained for all the patients at each visit to the hospital during the study. These points were obtained both before and when patients had achieved steady state conditions. At first glance, Fig. 1 suggests that serum Px concentrations are dose-dependent, but it does not take into account inter-patient variations that may exist. One of these patients required high doses of the drug (600 mg/day) to obtain sufficient serum Px concentrations and good therapeutic response, which suggested that not only are there different dose requirements between patients but that this type of information can be misleading.
During this study some patients received several dose alterations due to high serum Px concentrations or poor therapeutic response, and this provided valuable information of interpatient differences for the drug. Figure 2 shows the serum Px concentrations obtained for five different patients at different doses. The doses were plotted as mg/kg body weight. Serum Px concentrations were only plotted in this case when patients had achieved steady state conditions. This was verified by obtaining similar serum Px concentrations at different visits to the hospital. This could be up to 40 days after dose change due to the long half-life of the drug. s Gross differences in the dose kinetics between patients are evident. AlI the patients appear to show changes in rates of metabolism from first order to zero order kinetics. The dose at which saturation occurs varies considerably due to the different rates of hydroxylation of Px in people. Those patients at most risk from side-effects are those with ratios of serum Px concentrations/dose which are large at the point where zero order kinetics occur.
These differences in serum Px concentrations and dose between patients serve to amplify the highly cautious approach needed by clinicians for the therapeutic management of Px and the Monitoring of perhexiline maleate 617 necessity of having reliable estimations of the drug in serum if severe side-effects are to be avoided.
